Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. Montero AJ, et al. Among authors: singletary se. Cancer. 2005 Jul 15;104(2):229-35. doi: 10.1002/cncr.21182. Cancer. 2005. PMID: 15937910 Free article.
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Hanrahan EO, et al. Among authors: singletary se. Cancer. 2006 Jun 1;106(11):2327-36. doi: 10.1002/cncr.21906. Cancer. 2006. PMID: 16639731 Free article. Clinical Trial.
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Buzdar AU, et al. Among authors: singletary se. Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: singletary se. Clin Cancer Res. 2002 May;8(5):1073-9. Clin Cancer Res. 2002. PMID: 12006521 Clinical Trial.
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Buchholz TA, et al. Among authors: singletary se. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):880-8. doi: 10.1016/s0360-3016(02)02850-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12095553
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Meric F, et al. Among authors: singletary se. Cancer. 2003 Feb 15;97(4):926-33. doi: 10.1002/cncr.11222. Cancer. 2003. PMID: 12569592 Free article.
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. Garg AK, et al. Among authors: singletary se. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):138-45. doi: 10.1016/j.ijrobp.2003.10.037. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093909
286 results